CRNX

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

Wall Street analysts forecast CRNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRNX is 80.00 USD with a low forecast of 45.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Crinetics Pharmaceuticals Inc revenue for the last quarter amounts to 143.00K USD, decreased % YoY.

Crinetics Pharmaceuticals Inc. EPS for the last quarter amounts to -1.38 USD, increased 43.75 % YoY.

Crinetics Pharmaceuticals Inc (CRNX) has 437 emplpoyees as of December 15 2025.

Today CRNX has the market capitalization of 4.79B USD.